
Proteomics Market Analysis by Mordor Intelligence
The proteomics market size is estimated at USD 29.92 billion in 2025 and is projected to advance to USD 52.83 billion by 2030, reflecting a 12.04% CAGR. Expansion is propelled by rapid adoption of high-throughput mass-spectrometry systems, AI-enabled single-cell workflows, and growing integration of proteomic readouts into precision-medicine programs. Pharmaceutical firms are embedding proteomics across target discovery, lead optimization, and biomarker validation, while contract research organizations (CROs) scale specialized services. Regionally, continued R&D funding and entrenched biopharma infrastructure anchor North American leadership, whereas vigorous investment across China, India, Japan, and South Korea positions Asia-Pacific as the fastest-growing arena. Competitive dynamics centre on platform consolidation: large vendors acquire niche innovators to deliver end-to-end reagent, instrument, and analytics solutions that shorten project timelines for drug-development customers.
Key Report Takeaways
- By component, reagents led with 69.78% proteomics market revenue share in 2024; software and services are forecast to expand at a 13.56% CAGR through 2030.
- By technology, mass spectrometry commanded 30.69% of the proteomics market revenue share in 2024, while next-generation sequencing is projected to grow at 13.71% CAGR to 2030.
- By application, drug discovery and development captured 49.02% of the proteomics market size in 2024; precision and personalized medicine is advancing at a 14.23% CAGR to 2030.
- By end-user, pharmaceutical and biotechnology companies accounted for 73.54% demand in 2024; the CRO segment is rising at a 12.98% CAGR through 2030.
- By geography, North America contributed 44.31% of revenue in 2024, whereas Asia-Pacific is set to post a 13.84% CAGR to 2030.
Global Proteomics Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Rising demand for personalized & precision medicine | +2.8% | Global, with early gains in North America, Europe | Medium term (2-4 years) |
Increasing R&D expenditure and public funding | +2.1% | North America & EU, APAC core | Long term (≥ 4 years) |
Rapid advances in high-throughput MS & LC-MS platforms | +1.9% | Global | Short term (≤ 2 years) |
Growing adoption of proteomics in drug discovery pipelines | +1.7% | North America, Europe, spill-over to APAC | Medium term (2-4 years) |
AI-enabled single-cell proteomics breakthroughs | +1.4% | Global, concentrated in research hubs | Short term (≤ 2 years) |
Expanding use of proteomics in agri-genomics & food safety | +0.8% | APAC core, emerging in MEA | Long term (≥ 4 years) |
Source: Mordor Intelligence
Rising Demand for Personalized & Precision Medicine
Growing clinical evidence links protein-based biomarkers with disease stratification, fostering routine inclusion of proteomic panels in large cohort studies. Thermo Fisher Scientific's Olink platform’s selection[1]Thermo Fisher Scientific, “Olink Platform Selected for World’s Largest Human Proteome Study,” thermofisher.com for the UK Biobank’s programme to profile 5,400 proteins across 600,000 samples exemplifies this shift, creating multidimensional datasets that guide therapeutic selection. Proteomic fitness scores now complement genetic risk metrics and have demonstrated responsiveness to lifestyle interventions, underscoring value for preventive-care planning. Organ-specific ageing clocks derived from circulating protein signatures are informing early intervention strategies. Pharma stakeholders view these insights as pivotal for companion-diagnostic development, reinforcing sustained demand for next-generation assay platforms.
Increasing R&D Expenditure and Public Funding
Consortia funding models that pool biopharma and public financing are scaling infrastructure once limited to elite academic centres. The UK Biobank's proteomics initiative, funded by 14 biopharmaceutical companies[2]UK Biobank, “UK Biobank Pharma Proteomics Project,” ukbiobank.ac.uk, represents a paradigm shift where industry collaboration drives large-scale proteomic studies that were previously unfeasible. Government grants across China, Japan, and Korea subsidize high-resolution mass-spectrometry installations and cloud-based data hubs, lowering barriers for start-up laboratories. Venture capital flows toward AI-native proteomic software firms, accelerating automated pattern-recognition tools that cut analysis times from days to minutes and broaden user access.
Rapid Advances in High-Throughput MS & LC-MS Platforms
Instrument suppliers introduced successive flagship releases in 2024-25 that multiply scan speed and sensitivity. Thermo Fisher’s Stellar Mass Spectrometer reports 10-fold higher quantitative sensitivity, while Bruker’s timsTOF Ultra 2 boosts ion-capture efficiency toward 100%, enabling deeper proteome coverage per run. SCIEX’s ZT Scan DIA achieves tenfold acceleration over earlier data-independent workflows, supporting population-scale studies without sacrificing data quality. These gains collectively shorten acquisition windows, increase sample throughout, and make deep-profiling economically viable for translational projects.
Growing Adoption in Drug-Discovery Pipelines
Proteomics underpins every linkage from target validation to clinical-trial biomarker readouts. Bristol Myers Squibb allocated USD 400 million to collaborate with AI Proteins on miniprotein-based therapeutics. Pfizer’s engagement with Edelris brings proteomics-driven molecular-glue discovery into its small-molecule portfolio. Such deals illustrate how in-house discovery teams partner with specialist platforms to tackle previously undruggable proteins, expanding total addressable markets for precision treatments.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
High capital & operating cost of instruments | -1.8% | Global, particularly impacting smaller labs | Long term (≥ 4 years) |
Shortage of skilled bioinformaticians & proteomics experts | -1.2% | Global, acute in emerging markets | Medium term (2-4 years) |
Data-analysis complexity & lack of workflow standards | -0.9% | Global | Short term (≤ 2 years) |
Limited throughput for native membrane-protein studies | -0.6% | Global, research-focused impact | Medium term (2-4 years) |
Source: Mordor Intelligence
High Capital & Operating Cost of Instruments
Top-tier Orbitrap or trapped-ion-mobility platforms routinely exceed USD 1 million per system, and annual service contracts may add 10% of purchase price. Labs must also budget for consumables, vacuum infrastructure, and environmental controls. Although university-level initiatives such as the E3 method reduce sample-prep costs, hardware outlays remain a hurdle for mid-tier institutions. Shared-facility models and CRO outsourcing mitigate entry costs yet can constrain experimental flexibility.
Shortage of Skilled Bioinformaticians & Proteomics Experts
Analysis pipelines demand expertise spanning chemistry, statistics, and machine learning. Global demand for cross-trained scientists outpaces university graduates, creating wage inflation and hiring bottlenecks. Regulatory-grade workflows further require knowledge of CLIA-like validation standards, extending training timelines. Industry groups have responded with micro-credential programmes, but a structural talent gap persists, especially in fast-growing Asia-Pacific markets.
Segment Analysis
By Component: Dominance of Reagents and Momentum in Software
Reagents accounted for 69.78% of the proteomics market share in 2024, reflecting their consumable nature and indispensability across sample lysis, enrichment, labelling, and quantitation steps. High adoption of bioorthogonal tags that improve detection specificity sustains robust reorder volumes. The instruments sub-segment benefits from premium pricing on ultrahigh-resolution spectrometers designed for single-cell assays. Software and services are growing at a 13.56% CAGR as laboratories confront rising data volumes and seek AI-driven analytics platforms that remove bioinformatics bottlenecks. Cloud-native pipelines that integrate quality-control dashboards with automated annotation broaden accessibility for non-specialists, supporting overall proteomics market expansion.
Second paragraph: Adoption of subscription licensing accelerates vendor revenue, while managed-service contracts bundle instrument monitoring, data storage, and compliance reporting into predictable fees. CROs leverage modular software to offer rapid-turnaround studies, allowing smaller biotech companies to conduct discovery without installing costly hardware. As multi-omics integration becomes routine, hybrid workflows that co-analyze transcriptomic and proteomic layers rely on middleware capable of harmonizing heterogeneous datasets, further fueling demand for specialized analytics solutions within the proteomics market.
Note: Segment shares of all individual segments available upon report purchase
By Technology: Mass Spectrometry Leadership and NGS Upswing
Mass-spectrometry platforms captured 30.69% of the proteomics market share in 2024, owing to continuous innovation[3]Anatoly N. Verenchikov, “Multi-reflecting TOF MS for analyzing proteins,” International Journal of Mass Spectrometry, sciencedirect.com in ion-optics and detector design that extends resolving power past 200,000 for proteins up to 80 kDa. Time-of-flight-Orbitrap hybrids deliver sub-ppm mass accuracy at scan speeds supporting population-scale cohort studies. The proteomics market size tied to next-generation sequencing is forecast to expand at 13.71% CAGR, reflecting the converging utility of DNA-encoded libraries and ribosome-display systems in mapping protein-interaction networks. Sequencing-based readouts provide orthogonal validation of post-translational modifications and support high-multiplex quantitation.
Second paragraph: Complementary methods such as microfluidic-based separation and spatially resolved protein arrays gain traction for tissue-context analysis. Integration of chromatography upgrades, including ultra-high-pressure variants, enhances front-end separation and reduces sample carry-over, boosting confidence in low-abundance peptide identification. Vendors now package cross-platform kits that streamline transfer between LC-MS, capillary electrophoresis, and imaging-based workflows, ensuring method continuity for longitudinal studies within the proteomics market.
By Application: Drug-Discovery Scale and Precision-Medicine Acceleration
Drug discovery and development represented 49.02% proteomics market size in 2024 through its deep reliance on proteomic profiling for target validation, mode-of-action elucidation, and pharmacodynamic biomarker tracking. Adaptive trial designs incorporate real-time proteomic endpoints to expedite go/no-go decisions, thereby lowering attrition costs. Precision-medicine initiatives are projected to grow at 14.23% CAGR as health systems adopt multi-omic diagnostics to guide therapeutic selection. The proteomics market size associated with companion-diagnostic assays is expected to climb sharply as regulators endorse protein-signature panels for oncology and metabolic diseases.
Second paragraph: Clinical-diagnostic laboratories deploy multiplexed protein panels for early detection of neurodegeneration and cardiovascular risk. Agricultural and food-safety groups adopt targeted proteomics to verify allergen content and monitor crop pathogen resistance. Environmental agencies monitor emerging contaminants via protein bioindicators in sentinel species, extending commercial opportunities beyond healthcare. Academic consortia leverage shared repositories to cross-validate biomarker signatures, underscoring collaborative momentum inside the proteomics market.

Note: Segment shares of all individual segments available upon report purchase
By End-User: Pharma-Biotech Pre-eminence and CRO Surge
Pharmaceutical and biotechnology companies generated 73.54% of the proteomics market share in 2024 by embedding high-depth proteome profiling across discovery pipelines. Integration of label-free quantitation and structural proteomics accelerates time-to-candidate selection and informs rational combination therapies. CROs are advancing at a 12.98% CAGR as outsourcing mitigates capital burden and supplies specialized analytical depth. The proteomics market share accruing to CROs rises alongside their capacity to manage regulatory documentation and to deliver clinical-grade datasets.
Second paragraph: Academic institutions continue to spearhead fundamental technology advances, often in partnership with large instrumentation vendors that provide demonstration units in exchange for method-development insights. Government laboratories invest in biosurveillance and biodefence programmes, applying proteomic assays for pathogen fingerprinting. Food-testing facilities deploy targeted panels for quality-assurance programmes, adding non-pharma revenue streams that stabilize the overall growth of the proteomics market.
Geography Analysis
North America retained 44.31% of global revenue in 2024 due to an entrenched biopharma enterprise, sustained National Institutes of Health funding, and large-scale precision-medicine cohorts. The United States hosts leading vendors such as Thermo Fisher Scientific, which has closed 54 strategic acquisitions, averaging USD 3.09 billion, to deepen technology breadth. Canada expands through public-private genomics initiatives, while Mexico builds niche CRO capabilities serving regional generics manufacturers.
Europe recorded 11.96% CAGR with Germany, the United Kingdom, and France as principal contributors. The UK Biobank’s proteome programme exemplifies pan-European collaboration and underpins an ecosystem of contract-analysis providers that interpret multi-omic datasets for pharma sponsors. Germany leverages domestic precision-instrument engineering to export high-performance LC-MS systems, whereas France and Italy scale clinical trial networks that integrate proteomics endpoints, strengthening the proteomics market across the continent.
Asia-Pacific is positioned as the fastest-growing region at 13.84% CAGR through 2030. China’s Five-Year Plan earmarks biotechnology as a strategic pillar, and patent grants for novel diagnostic panels validate domestic innovation capacity. India draws investment into cost-effective CRO hubs and establishes joint-degree programmes in proteogenomics to alleviate talent shortages. Japan pioneers robotics-enabled sample preparation, while South Korea subsidizes AI-native bio-informatics start-ups. Australia’s translational research alliances focus on agrigenomics and rare-disease diagnostics, broadening the addressable proteomics market. Middle East and Africa show progressive adoption in tertiary hospitals, and Brazil leads South American uptake through vaccine-related proteome studies.

Competitive Landscape
Competition is marked by consolidation among instrument suppliers pursuing vertically integrated solutions. Thermo Fisher’s USD 3.1 billion acquisition of Olink in July 2024 unites proximity-extension assays with Orbitrap mass-spectrometry, creating a broad sample-to-insight workflow. Bruker completed an EUR 870 million purchase of ELITech[4]Bruker Corporation, “Bruker Completes Acquisition of ELITech,” bruker.com to reinforce diagnostic-kit offerings that feed downstream mass-spectrometry confirmation. Quanterix integrated Akoya Biosciences’ spatial-omics portfolio to deliver both blood-based and tissue-context protein biomarker detection.
Strategic partnerships escalate discovery pipelines: Bristol Myers Squibb signed a USD 400 million deal with AI Proteins to co-develop miniprotein therapeutics. Orionis Biosciences secured USD 105 million upfront from Genentech for molecular-glue drug discovery. Vendors differentiate through proprietary AI algorithms that automate peptide-spectra matching, reduce false-positive identifications, and enable real-time feedback during chromatographic runs. Smaller disruptors focus on cloud-native lab-in-a-box solutions that shrink hardware footprints and appeal to decentralized research teams.
Market entrants specializing in single-cell proteomics incorporate acoustic droplet-ejection and nanoflow LC to boost sensitivity at sub-picogram levels. Integration of rapid-sample tag chemistries with ultra-high-resolution mass analyzers delivers cell-to-cell heterogeneity insights critical for immuno-oncology programmes. Established players respond by launching upgrade pathways that plug next-gen front-end modules into installed bases, protecting share within the proteomics market.
Proteomics Industry Leaders
-
Agilent Technologies, Inc.
-
Bio-Rad Laboratories, Inc.
-
Bruker Corporation
-
Danaher Corporation
-
Thermo Fisher Scientific Inc.
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- June 2025: Thermo Fisher Scientific introduced Orbitrap Astral Zoom and Orbitrap Excedion Pro with 35% faster scan speeds and 50% higher multiplexing, targeting biopharma QC and multi-omics workflows.
- June 2025: UCLA and University of Toronto released moPepGen, a software tool that detects four-times more unique protein variants than earlier methods, advancing cancer-genomics research.
- May 2025: Orionis Biosciences entered a partnership with Genentech that could yield over USD 2 billion in milestone payments to develop molecular-glue oncology medicines.
- May 2025: Proteomics International Laboratories obtained a Chinese patent for its muscle-stress diagnostic, extending protection until 2039 and strengthening its sports-medicine portfolio.
Global Proteomics Market Report Scope
Proteomics is the study of protein structure and function. At the cellular level, proteomics deal with the topics, such as which proteins are expressed, when and where they are expressed, what their structures in both active and inactive states are, what roles they play in the life of the cell, and how they interact with other proteins and molecules.
By Component | Instruments | ||
Reagents | |||
Software and Services | |||
By Technology | Mass Spectrometry | ||
Spectroscopy | |||
Chromatography | |||
Next-Generation Sequencing | |||
Protein Microarrays | |||
Microfluidics | |||
X-ray Crystallography | |||
Other Technologies | |||
By Application | Drug Discovery & Development | ||
Clinical Diagnostics | |||
Biomarker Discovery | |||
Precision and Personalized Medicine | |||
Agricultural & Environmental Proteomics | |||
Other Applications | |||
By End-User | Pharmaceutical & Biotechnology Companies | ||
Academic & Research Institutes | |||
Contract Research Organizations | |||
Other End-Users | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
India | |||
Japan | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Instruments |
Reagents |
Software and Services |
Mass Spectrometry |
Spectroscopy |
Chromatography |
Next-Generation Sequencing |
Protein Microarrays |
Microfluidics |
X-ray Crystallography |
Other Technologies |
Drug Discovery & Development |
Clinical Diagnostics |
Biomarker Discovery |
Precision and Personalized Medicine |
Agricultural & Environmental Proteomics |
Other Applications |
Pharmaceutical & Biotechnology Companies |
Academic & Research Institutes |
Contract Research Organizations |
Other End-Users |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
India | |
Japan | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
Why are reagents the most purchased products in the proteomics industry?
Every laboratory run requires fresh reagents for sample preparation, labeling, and quantification, so repeat purchasing drives constant revenue and keeps this category ahead of instruments and software.
How is artificial intelligence changing single-cell proteomics?
AI algorithms now automate peptide-spectra matching and pattern recognition, allowing researchers to extract meaningful insights from thousands of individual cells in hours instead of days.
What factors make Asia-Pacific the fastest-expanding proteomics hub?
Governments across China, India, Japan, and South Korea fund new biotech parks, subsidize high-resolution mass-spectrometry installations, and foster academic–industry partnerships that accelerate technology adoption.
Which end-user group is outsourcing proteomics services the most and why?
Mid-size pharmaceutical and biotechnology firms increasingly rely on contract research organizations to access advanced instrumentation and regulatory-grade workflows without making large capital investments.
How are mergers and acquisitions influencing market competition?
Large instrument vendors are buying niche assay and software developers to offer end-to-end platforms, giving customers seamless workflows from sample to insight and consolidating supplier options.
What is the biggest operational challenge facing labs that adopt next-generation proteomics hardware?
The shortage of cross-trained scientists who can operate complex instruments and interpret data sets slows project timelines and limits the pace at which new systems can be deployed.
Page last updated on: June 23, 2025